Rein Therapeutics
RNTX | NASDAQ
$0.40
-$0.15 (-27.55%)
At close: Nov 16, 2026, 4:00 PM ET
$0.38
-$0.02 (-5.35%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-27.55%
(1D)No price chart data available for 1D timeframe.
Rating
36.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #621/1021 (Top 61%)
Key Statistics
Market Data
Market Cap $34.51M
1D Range
0.28 0.50
52W Range
0.28 1.88
Valuation (TTM)
PE -0.22
PB 3.38
EV/EBITDA 0.29
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $6.00
Cash Flow
FCF Yield -54.6%
SBC Adj. FCF Yield -60.4%
SBC Impact -10.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 27.4% |
24.9%
FCF 3Y | 5Y -9.6% |
7.0%
Returns
ROA -75.4%
ROE -234.4%
ROIC -36.4%
Financial Health
Net Cash
$40.65M
Current Ratio 4.27
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The c...
Sector Healthcare
Industry Biotechnology
Employees 10
IPO Date Jun 29, 2017
Website www.reintx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$6.00
Upside
+1400.00%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove RNTX